Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedules of Concentration of Risk, by Risk Factor

A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:

	Revenue						Accounts Receivable
	Year Ended December 31,						As of December 31,
	2019		2018		2017		2019		2018
Customer A	*		*		13	%	*		*
Customer B	26	%	18	%	13	%	40	%	65	%
Customer C	*		*		*		10	%	*
Customer D	14	%	*		*		*		*

*

less than 10%

Property, Plant and Equipment

Estimated useful lives for property and equipment are as follows:

Property and Equipment	Estimated Useful Life
Machinery and equipment	3 – 5 years
Furniture and fixtures	7 years
Computer hardware and computer software	3 years
Leasehold improvements	Lesser of estimated useful life or remaining lease term

Property and equipment, net consist of the following:

	As of December 31,
	2019			2018
	(in thousands)
Machinery and equipment	$	29,119		$	23,440
Computer hardware	6,296			4,949
Leasehold improvements	21,031			13,965
Furniture and fixtures	1,962			1,522
Computer software	829			643
Construction in progress	6,354			3,118
Property and equipment, gross	65,591			47,637
Less: accumulated depreciation and amortization	(21,923		)	(16,634		)
Property and equipment, net	$	43,668		$	31,003

Schedule of Impact of Adoption of ASC 606

The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:

	As of December 31, 2018			Adjustments due to ASC 606		As of January 1, 2019
	(in thousands)
Assets:
Accounts receivable	$	35,690		$	4,907	$	40,597
Equity:
Accumulated deficit	$	(280,799	)	$	4,907	$	(275,892	)

In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company’s consolidated statement of operations and consolidated balance sheet was as follows:

	For the year ended December 31, 2019
	As Reported Under ASC 606		Effect of Change			Balances Without Adoption of ASC 606
	(in thousands)
Revenue:
Precision oncology testing	$	180,462	$	(347	)	$	180,115
Development services	$	33,913	$	—		$	33,913

	As of December 31, 2019
	As Reported Under ASC 606			Effect of Change			Balances Without Adoption of ASC 606
	(in thousands)
Assets:
Accounts receivable	$	47,986		$	(347	)	$	47,639
Equity:
Accumulated deficit	$	(352,809	)	$	(347	)	$	(353,156	)